公开(公告)号：WO9722619A3

公开(公告)日：1997-10-16

申请号：PCT/US9620843

申请日：1996-12-20

Applicant: VERTEX PHARMA

Inventor： BATCHELOR MARK J ,  BEBBINGTON DAVID ,  BEMIS GUY W ,  FRIDMAN WOLF HERMAN ,  GILLESPIE ROGER J ,  GOLEC JULIAN M C ,  GU YONG ,  LAUFFER DAVID J ,  LIVINGSTON DAVID J ,  MATHARU SAROOP S ,  MULLICAN MICHAEL D ,  MURCKO MARK A ,  MURDOCH ROBERT ,  NYCE PHILIP L ,  ROBIDOUX ANDREA L C ,  SU MICHAEL ,  WANNAMAKER M WOODS ,  WILSON KEITH P ,  ZELLE ROBERT E

IPC: C07D243/12 ,  A61K31/55 ,  A61K31/551 ,  A61K31/553 ,  A61K31/675 ,  A61K38/00 ,  A61K38/04 ,  A61K38/05 ,  A61K38/06 ,  A61K38/07 ,  A61K38/55 ,  A61P13/12 ,  A61P19/08 ,  A61P19/10 ,  A61P25/00 ,  A61P25/28 ,  A61P29/00 ,  A61P31/00 ,  A61P31/04 ,  A61P35/00 ,  A61P37/00 ,  A61P37/06 ,  A61P43/00 ,  C07D243/10 ,  C07D243/14 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D409/12 ,  C07D413/12 ,  C07D417/12 ,  C07D471/04 ,  C07D473/00 ,  C07D487/04 ,  C07D491/048 ,  C07D495/04 ,  C07D498/04 ,  C07D513/04 ,  C07D519/00 ,  C07F9/645 ,  C07F9/6561 ,  C07K5/02 ,  C07K5/023 ,  C07K5/06 ,  C07K5/078 ,  C07K5/097 ,  A61K38/08

CPC classification number: C07D243/12 ,  A61K38/00 ,  C07D401/06 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D413/12 ,  C07D417/12 ,  C07D471/04 ,  C07D487/04 ,  C07K5/0202 ,  C07K5/06139 ,  C07K5/0821

Abstract: The present invention relates to novel classes of compounds which are inhibitors of interleukin-1² converting enzyme. The ICE inhibitors of this invention are characterized by specific structural and physiochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting ICE activity and consequently, may be advantageously used as agents against IL-1-, apoptosis-, IGIF-, and IFN-³-mediated diseases, inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, degenerative diseases, and necrotic diseases. This invention also relates to methods for inhibiting ICE activity, for treating interleukin-1-, apoptosis-, IGIF-, and IFN-³-mediated diseases and decreasing IGIF, and IFN-³ production using the compounds and compositions of this invention. This invention also relates to methods for preparing N-acylamino compounds.

公开(公告)号：HK1089435A1

公开(公告)日：2006-12-01

申请号：HK06109752

申请日：2006-09-01

Applicant: VERTEX PHARMA

Inventor： BATCHELOR MARK J ,  BEBBINGTON DAVID ,  BEMIS GUY W ,  FRIDMAN WOLF HERMAN ,  GILLESPIE ROGER J ,  GOLEC JULIAN M C ,  GU YONG ,  LAUFFER DAVID J ,  LIVINGSTON DAVID J ,  MATHARU SAROOP S ,  MULLICAN MICHAEL D ,  MURCKO MARK A ,  MURDOCH ROBERT ,  NYCE PHILIP L ,  ROBIDOUX ANDRES L C ,  MICHAEL SU ,  WANNAMAKER M WOODS ,  WILSON KEITH P ,  ZELLE ROBERT E

IPC: C07D243/12 ,  A61K20090101 ,  A61K31/55 ,  A61K31/551 ,  A61K31/553 ,  A61K31/675 ,  A61K38/00 ,  A61K38/04 ,  A61K38/05 ,  A61K38/06 ,  A61K38/07 ,  A61K38/55 ,  A61P20090101 ,  A61P13/12 ,  A61P19/08 ,  A61P19/10 ,  A61P25/00 ,  A61P25/28 ,  A61P29/00 ,  A61P31/00 ,  A61P31/04 ,  A61P35/00 ,  A61P37/00 ,  A61P37/06 ,  A61P43/00 ,  C07D20090101 ,  C07D243/10 ,  C07D243/14 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D409/12 ,  C07D413/12 ,  C07D417/12 ,  C07D471/04 ,  C07D473/00 ,  C07D487/04 ,  C07D491/048 ,  C07D495/04 ,  C07D498/04 ,  C07D513/04 ,  C07D519/00 ,  C07F9/645 ,  C07F9/6561 ,  C07K5/02 ,  C07K5/023 ,  C07K5/06 ,  C07K5/078 ,  C07K5/097

Abstract: The present invention relates to novel classes of compounds which are inhibitors of interleukin-1² converting enzyme. The ICE inhibitors of this invention are characterized by specific structural and physiochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting ICE activity and consequently, may be advantageously used as agents against IL-1-, apoptosis-, IGIF-, and IFN-³-mediated diseases, inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, degenerative diseases, and necrotic diseases. This invention also relates to methods for inhibiting ICE activity, for treating interleukin-1-, apoptosis-, IGIF-, and IFN-³-mediated diseases and decreasing IGIF, and IFN-³ production using the compounds and compositions of this invention. This invention also relates to methods for preparing N-acylamino compounds.

公开(公告)号：PL191249B1

公开(公告)日：2006-04-28

申请号：PL33328697

申请日：1997-11-13

Applicant: VERTEX PHARMA

Inventor： ZELLE ROBERT E ,  SU MICHAEL

IPC: A61K38/00 ,  A61K31/44 ,  A61K38/18 ,  A61K31/445 ,  A61K38/22 ,  A61K45/06 ,  A61P25/00 ,  A61P25/02 ,  A61P25/14 ,  A61P25/16 ,  A61P25/28

公开(公告)号：PL190903B1

公开(公告)日：2006-02-28

申请号：PL33327097

申请日：1997-11-13

Applicant: VERTEX PHARMA

Inventor： ZELLE ROBERT E ,  SU MICHAEL

IPC: A61K38/18 ,  A61K38/22 ,  A61K31/44 ,  A61K38/00 ,  A61K45/06 ,  A61P9/10 ,  A61P25/00 ,  A61P25/16 ,  A61P25/28

公开(公告)号：IS2057B

公开(公告)日：2005-10-14

申请号：IS5032

申请日：1999-04-21

Applicant: VERTEX PHARMA

Inventor： ZELLE ROBERT E ,  SU MICHAEL

IPC: A61K38/22 ,  A61K31/44 ,  A61K38/00 ,  A61K38/18 ,  A61K45/06 ,  A61P9/10 ,  A61P25/00 ,  A61P25/16 ,  A61P25/28

公开(公告)号：SK284535B6

公开(公告)日：2005-06-02

申请号：SK62899

申请日：1997-11-13

Applicant: VERTEX PHARMA

Inventor： ZELLE ROBERT E ,  SU MICHAEL

IPC: A61K38/22 ,  A61K31/44 ,  A61K38/00 ,  A61K38/18 ,  A61K45/06 ,  A61P9/10 ,  A61P25/00 ,  A61P25/16 ,  A61P25/28

Abstract: Described is the pharmaceutical composition for stimulating the growth of neurites in nerve cells, which comprises a neurotrophic amount of a compound of the general formula (I) such as nerve growth factor (NGF). Next is described a using of compound of the general formula (I) for preparing medicament for stimulating the growth of nerve cells.

公开(公告)号：ES2216022T3

公开(公告)日：2004-10-16

申请号：ES95939156

申请日：1995-11-13

Applicant: VERTEX PHARMA

Inventor： ZELLE ROBERT E ,  HARDING MATTHEW W

IPC: C07C237/00 ,  C07D333/06 ,  A61K31/00 ,  A61K31/16 ,  A61K31/165 ,  A61K31/395 ,  A61K31/41 ,  A61K31/42 ,  A61K31/421 ,  A61K31/4245 ,  A61K31/44 ,  A61K31/4406 ,  A61K31/4409 ,  A61K31/4418 ,  A61P35/00 ,  C07C231/02 ,  C07C237/22 ,  C07C309/51 ,  C07C309/59 ,  C07C317/28 ,  C07C323/41 ,  C07D213/38 ,  C07D213/40 ,  C07D213/50 ,  C07D213/56 ,  C07D233/54 ,  C07D233/90 ,  C07D261/08 ,  C07D263/32 ,  C07D271/04 ,  C07D277/20 ,  C07D277/22 ,  C07D277/38 ,  C07D277/64 ,  C07D333/36 ,  C07D521/00 ,  C07C237/02 ,  C07D213/81

公开(公告)号：PT797567E

公开(公告)日：2004-06-30

申请号：PT95939156

申请日：1995-11-13

Applicant: VERTEX PHARMA

Inventor： HARDING MATTHEW W ,  ZELLE ROBERT E

IPC: C07C237/00 ,  C07D333/06 ,  A61K31/00 ,  A61K31/16 ,  A61K31/165 ,  A61K31/395 ,  A61K31/41 ,  A61K31/42 ,  A61K31/421 ,  A61K31/4245 ,  A61K31/44 ,  A61K31/4406 ,  A61K31/4409 ,  A61K31/4418 ,  A61P35/00 ,  C07C231/02 ,  C07C237/22 ,  C07C309/51 ,  C07C309/59 ,  C07C317/28 ,  C07C323/41 ,  C07D213/38 ,  C07D213/40 ,  C07D213/50 ,  C07D213/56 ,  C07D233/54 ,  C07D233/90 ,  C07D261/08 ,  C07D263/32 ,  C07D271/04 ,  C07D277/20 ,  C07D277/22 ,  C07D277/38 ,  C07D277/64 ,  C07D333/36 ,  C07D521/00 ,  C07C237/02 ,  C07D213/81

公开(公告)号：AP1280A

公开(公告)日：2004-05-21

申请号：AP9801294

申请日：1996-12-20

Applicant: VERTEX PHARMA

Inventor： BATCHELOR MARK J ,  BEBBINGTON DAVID ,  BEMIS GUY ,  FRIDMAN WOLF HERMAN ,  GILLESPIE ROJER J ,  GOLEC JULIAN M ,  GU YONG ,  LAUFFER DAVID J ,  LIVINGSTONE DAVID J ,  MATHARU SAROOP S ,  MULLICAN MICHAEL D ,  MURCKO MARK A ,  MURDOCH ROBERT D ,  NYCE PHILLIP L ,  ROBIDOUX ANDREA L C ,  SU MICHAEL ,  WANNAMAKER MARION WOODS ,  WILSON KEITH P ,  ZELLE ROBERT E

IPC: C07K5/02

Abstract: This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting ICE activity and consequently, may be advantageously used as agents against IL-1-, apoptosis-, IGIF-, and IFN-y-mediated diseases, inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, degenerative diseases, and necrotic diseases. This invention also relates to methods for inhibiting ICE activity, for treating interleukin-1-, apoptosis-, IGIF- and IFN-y-mediated diseases and decreasing IGIF and IFN-y production using the compounds and compositions of this invention.

公开(公告)号：AT250424T

公开(公告)日：2003-10-15

申请号：AT97947533

申请日：1997-11-13

Applicant: VERTEX PHARMA

Inventor： ZELLE ROBERT E ,  SU MICHAEL

IPC: A61K38/22 ,  A61K31/44 ,  A61K38/00 ,  A61K38/18 ,  A61K45/06 ,  A61P9/10 ,  A61P25/00 ,  A61P25/16 ,  A61P25/28

Abstract: The present invention relates to methods and pharmaceutical compositions for stimulating the growth of neurites in nerve cells. The compositions comprise a neurotrophic amount of a compound and a neurotrophic factor, such as nerve growth factor (NGF). The methods comprise treating nerve cells with the above compositions or compositions comprising the compound without a neurotropic factor. The methods of this invention can be used to promote repair of neuronal damage caused by disease or physical trauma.